Navigation Links
Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
Date:10/12/2010

CHAPEL HILL, N.C., Oct. 12 /PRNewswire/ -- Cempra Pharmaceuticals announced that Richard Kent, M.D., a partner at Intersouth Partners, has been appointed to Cempra's board of directors.  Dr. Kent will replace Garheng Kong, M.D., Ph.D., M.B.A., as Intersouth's representative on the board.   Dr. Kong, who has recently taken a position as a general partner at Sofinnova Ventures, will continue as Cempra's chairman of the board.

Dr. Kent brings extensive pharmaceutical management and drug development experience to the Cempra board.  During his over 25 years in the pharmaceutical industry, he supervised dozens of Investigational New Drug (IND) applications and over 20 successful New Drug Applications (NDAs) in a wide range of therapeutic areas.  Prior to joining Intersouth Partners, he was chief executive officer of Serenex, Inc., a venture-backed biotechnology company that was acquired by Pfizer in 2008.  He also held a number of senior positions at Burroughs Wellcome, GlaxoWellcome and GlaxoSmithKline.  Dr. Kent received his M.D. from the University of California, San Diego and his B.Sc. from the University of California, Berkeley.

"Adding Dr. Kent to our board, with his experience both in shepherding NDAs through to regulatory approval and his involvement with Serenex's transaction with Pfizer, is an important step for Cempra," said Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra Pharmaceuticals.  "We have two differentiated antibiotic candidates in mid-to-late stage clinical development.  His advice will be invaluable as both of our antibiotics move forward towards an NDA as well as assisting us with our partnering strategy."

Dr. Kent added, "Cempra's two antibiotic candidates have significant commercial potential in a therapeutic area that needs new options for physicians and patients but suffers from a lack of new drug candidates.  I am looking forward to working with the Cempra team to contribute strategy and direction to bring these two drug candidates to the market."

About Cempra PharmaceuticalsFounded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.Media Contacts:Russo Partners, LLCRobert E. Flamm, Ph.D.(212) 845-4226Robert.flamm@russopartnersllc.comTony Russo, Ph.D.(212) 845-4251Tony.russo@russopartnersllc.com
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
2. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
3. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
4. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
5. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , December 5, 2016 BioLineRx ... in-licensing and developing promising therapeutic candidates, presents positive Phase 2a ... the Company,s leading oncology platform at the ongoing 58th American ... San Diego, California . ... , , ...
(Date:12/5/2016)... The global  non-invasive prenatal testing market  is anticipated ... by Grand View Research, Inc. Evolution of prenatal testing in the form ... screening and invasive diagnostic testing to determine the likelihood of fetal abnormality ... forecast period. Continue Reading ... ...
(Date:12/4/2016)... -- Johnson & Weaver, LLP announces that a class action ... Holdings, Inc. (NYSE: ZBH )  securities during the ... "Class Period"). Zimmer Biomet provides musculoskeletal healthcare products ... such as knee and hip reconstructive products. ... , , ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... Routine ... measurements are consistently correct. However, regular performance testing is often neglected because ... a solution: SmartCal™ . This innovative test substance offers a fast ...
(Date:12/4/2016)... (PRWEB) , ... December 03, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... hosted its first Swirl: A Wine Tasting Event in New York City, with ...
(Date:12/4/2016)... ... December 04, 2016 , ... "Pro3rd Displace ... animation styles with unique displacement design elements," said Christina Austin - CEO of ... Choose from a variety of design styles that include both left aligned and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Advanced Inc., a ... has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, ... Inc. , Jason brings extensive financial and operational leadership experience to Advanced Inc. ...
Breaking Medicine News(10 mins):